Chen Hao, Lei Yeqing, Zhou Junjie, Lv Chenhui, Xuan Qijia
Department of Oncology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
Department of Gastroenterology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
Front Oncol. 2025 Mar 26;15:1552914. doi: 10.3389/fonc.2025.1552914. eCollection 2025.
Bevacizumab is a primary focus in the clinical application and research of metastatic colorectal cancer (mCRC) patients. This study aims to analyze publications on bevacizumab and CRC to explore and identify the trends and frontiers of this field.
We collected 4,164 articles on bevacizumab and CRC from the Web of Science Core Collection (WoSCC). CiteSpace, VOSviewer, R-bibliometrix, and Microsoft Excel were utilized for analysis and visualization.
The United States, Japan, and China are the leading countries in this field. The National Cancer Institute and the University of Pisa share the top position for the highest number of publications. Personalized therapy, innovative combination treatments, mechanisms of resistance, and new drug development are enduring focal points and future research directions.
This study provides the first bibliometric analysis of research on bevacizumab and CRC, revealing the current status and future directions of this field.
贝伐单抗是转移性结直肠癌（mCRC）患者临床应用和研究的主要焦点。本研究旨在分析关于贝伐单抗与结直肠癌的出版物，以探索和确定该领域的趋势与前沿。
我们从科学网核心合集（WoSCC）收集了4164篇关于贝伐单抗与结直肠癌的文章。使用CiteSpace、VOSviewer、R-文献计量学和微软Excel进行分析与可视化。
美国、日本和中国是该领域的领先国家。美国国立癌症研究所和比萨大学在出版物数量上并列第一。个性化治疗、创新联合治疗、耐药机制和新药开发是持久的焦点及未来研究方向。
本研究首次对贝伐单抗与结直肠癌的研究进行文献计量分析，揭示了该领域的现状和未来方向。
Zotero 插件
